Cancer Therapies May Trigger Aging Phenotypes in Survivors

Share this content:
Cancer Therapies May Trigger Aging Phenotypes in Survivors
Cancer Therapies May Trigger Aging Phenotypes in Survivors

TUESDAY, Dec. 19, 2017 (HealthDay News) -- Cancer therapies have direct effects on telomere length, epigenetic modifications, and microRNA, which can mimic phenotypes of aging, according to a review published online Dec. 18 in ESMO Open.

Noting that cancer survivors have an earlier onset and increased incidence of chronic comorbidities than the general population, Margaret C. Cupit-Link, from the Mayo Clinic in Rochester, Minn., and colleagues conducted a systematic review to examine the cellular biology of aging and/or mechanisms of cancer therapies similar to aging mechanisms.

The researchers identified multiple biological processes of aging at the cellular level and correlations with cancer therapies and clinical effects. Various chemotherapies and radiation had direct effects on telomere length, senescent cells, epigenetic modifications, and microRNA. Cancer survivors exhibited long-term comorbidities that mimic the phenotypes of aging and may result from the interaction between therapeutic exposures and the underlying biology of aging.

"Long-term follow-up of cancer survivors and research on prevention strategies should be pursued to increase the length and quality of life among the growing population of cancer survivors," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »